Savage Brian 4

What Happened

• Brian Savage, Interim Chief Legal Officer of Teva Pharmaceutical (TEVA), had restricted share units (RSUs) convert/settle and an award recorded on March 4, 2026. The filing shows an award/acquisition of 11,280 shares and conversion/settlement entries for vested RSU tranches. To cover tax withholding, Savage sold 2,675 shares in open-market transactions for total proceeds of $86,843 (reported weighted average price $32.46).

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely).
• Sales: 1,489 shares sold for $48,340 and 1,186 shares sold for $38,503; weighted average price $32.46; individual trade prices ranged $32.095–$33.30 (footnote).
• Award/settlement: Filing shows RSU conversion/award activity (listed as derivative conversions (M) and an award (A) for 11,280 shares; several derivative disposals are shown at $0.00 reflecting net/derivative settlement).
• Tax withholding: Footnote indicates the shares sold were required to be sold to cover tax withholding on RSU vesting (routine withholding); derivative disposals at $0.00 reflect net-settlement/withholding.
• Shares owned after transaction: not specified in the publicly provided excerpt of the filing.
• Codes explained: S = open-market sale; M = conversion/exercise of a derivative (here, RSU settlement); A = award/grant; F notes give vesting history for the RSUs.

Context

• This appears to be a routine RSU vesting and settlement event, not an open-market purchase (no new buy). Part of the vested shares were sold to satisfy tax withholding obligations (common practice), while the remainder were retained. Derivative/zero-dollar disposition lines reflect net settlement or shares withheld for taxes rather than a market sale.